MALARONE PEDIATRIC Rx
Generic Name and Formulations:
Atovaquone 62.5mg, proguanil HCl 25mg; tabs.
Indications for MALARONE PEDIATRIC:
Prophylaxis of P. falciparum malaria (including chloroquine-resistant strains). Treatment of acute uncomplicated P. falciparum malaria.
Adults and Children:
Take at the same time each day with food or a milky drink. Children: may crush and mix with condensed milk if unable to swallow tabs. Repeat dose if vomiting occurs within 1 hour. Prophylaxis (once daily starting 1–2 days before entering endemic area, during stay, and for 7 days after return): <11kg: not recommended (see Treatment); 11–20kg: 62.5mg atovaquone/25mg proguanil; 21–30kg: 125mg/50mg; 31–40kg: 187.5mg/75mg. >40kg: 250mg/100mg. Treatment (give as single daily dose for 3 consecutive days): <5kg: not recommended; 5–8kg: 125mg/50mg; 9–10kg: 187.5mg/75mg; 11–20kg: 250mg/100mg; 21–30kg: 500mg/200mg; 31–40kg: 750mg/300mg. >40kg: 1g/400mg.
Prophylaxis in severe renal impairment (CrCl <30mL/min).
Use other therapy in severe malaria, recrudescence, or prophylaxis failure. Monitor parasitemia closely and consider other therapy in severe or persistent diarrhea or vomiting (may use antiemetics). Hepatic or renal impairment (CrCl <30mL/min): consider alternate therapy for treatment. Elderly. Pregnancy (Cat.C; may continue folate supplements). Nursing mothers.
Concomitant rifampin, rifabutin: not recommended. Atovaquone antagonized by tetracycline, metoclopramide. Proguanil may potentiate warfarin or other coumarin-based anticoagulants (monitor). Caution with indinavir, CYP2C19 substrates or inhibitors.
Naphthoquinone + dihydrofolate reductase inhibitor.
GI upset/pain, headache, asthenia, anorexia, dizziness, elevated liver function tests; rare: anaphylaxis, vasculitis, hepatitis, cholestasis. Children: vomiting, pruritus.
Tabs—24, 100; Ped tabs—100
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Breast Cancer Screening Recommendations Not Completely Reflective of Race, Age
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|